Weekly paclitaxel as second/third-line treatment in advanced non-small cell lung cancer patients: Efficacy and tolerability

Anticancer Research

Volumn 25, Issue 6 C, 2005, Pages 4611-4614

  Camps, Carlos ^a   Caballero, Cristina ^a   Blasco, Ana ^a   Safont, Maria Jose ^a   Berrocal, Alfonso ^a   Garde, Javier ^a   Juarez, Asunción ^a   Sirera, Rafael ^a   Bremnes, Roy M ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Efficacy; Non small cell lung cancer; NSCLC; Toxicity; Weekly paclitaxel

Indexed keywords

PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANAPHYLAXIS; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER GRADING; CANCER GROWTH; CANCER PAIN; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FEASIBILITY STUDY; FEMALE; FEVER; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OUTPATIENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SENSORY NEUROPATHY; SYMPTOMATOLOGY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VISUAL ANALOG SCALE; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; TREATMENT OUTCOME;

EID: 28444441541     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Landis SH et al: Cancer statistics 1998. CA Cancer J Clin 48 (1): 6-29, 1998.
2. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311(7010): 899-909, 1995.
3. Shepherd FA: Chemotherapy for non-small cell lung cancer: have we reached a new plateau? Semin Oncol 26(1 Suppl 4): 3-11, 1999.
4. Pfister DG et al: American society of clinical oncology treatment of unresectable non-small cell lung cancer guideline: Update 2003. J Clin Oncol 15(2): 330-353, 2004.
5. Crinó L et al: Gemcitabine as second-line treatment for advanced non-small cell lung cancer: a phase II trial. J Clin Oncol 17(7): 2081-2089, 1999.
6. Pectasides D et al: An out-patients second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic co-operative oncology group. Anticancer Res 21(4B): 3005-3010, 2001.
7. Camps C, Martinez EN and Jaime AB: Second-line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: a pilot study. Lung Cancer 27(7): 47-53, 2000.
8. Gandara D et al: Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol 18(1): 131-135, 2000.
9. Belani CP: Single agents in the second-line treatment of non-small cell lung cancer. Semin Oncol 25(3 Suppl 8): S10-S14, 1998.
10. Fossella FV et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18(12): 2354-2362, 2000.
11. Chang AY et al: Phase II study of taxol, merbarorne and piroxantrone in stage IV non-small cell lung cancer: The Eastern Oncology Cooperative Group results. J. Natl Cancer Inst 85(5): 388-394, 1993.
12. Hainsworth JD, Thompson DS and Greco FA: Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol 13(7): 1609-1614, 1995.
13. Tester WJ et al: Phase II study of patients with metastatic non-small cell carcinoma of the lung treated with paclitaxel by 3-hour infusion. Cancer 79(4): 724-729, 1997.
14. Akerley W: Recent development in weekly paclitaxel therapy in lung cancer. Curr Oncol Rep 3(2): 165-169, 2001.
15. Juan O et al: Low-dose weekly paclitaxel as second-line treatment for advanced non-small cell lung cancer: a phase II study. Jpn J Clin Oncol 32(11): 449-454, 2002.
16. Massuti B et al: Weekly paclitaxel in non-small cell lung cancer: Results in older or frail patients. A Spanish Lung Cancer Group Trial (GECP 00-02). Proc Am Soc Clin Oncol 23: 736, 2004.
17. National Cancer Institute. Cancer therapy evaluation program: Guidelines for the reporting of adverse drug reactions. Common toxicity criteria v2.0 (CTC), 1999. (http://ctep. cancer.gov/reporting/CTC-3.html).
18. Miller AB et al: Reporting results of cancer treatment. Cancer 47(1): 207-214, 1981.
19. Shepherd FA et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18(10): 2095-2103, 2000.
20. Hanna NH et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22(9): 1589-1597, 2004.
21. Seidman AD et al: Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer J Clin Oncol 14(6): 1877-1884, 1996.
22. Fennelly D et al: Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1(1): 187-192, 1997.
23. Yeung TK et al: The mode of action of taxol: apoptosis at low concentration and necrosis at high concentration. Biochem Biophys Res Commun 263(2): 398-404, 1999.
24. Camps C et al, for the Spanish Lung Cancer Group: Second-line docetaxel administrated every 3 weeks versus weekly in advanced non-small-cell lung cancer (NSCLC): A Spanish Lung Cancer Group (SLCG) phase III trial. Proc Am Soc Clin Oncol 22: 625, 2003.
25. Chang A et al: Weekly moderate-dose paclitaxel in stage IV non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 17: 420, 1998.
26. Murphy WK, Winn RJ and Huber M: Phase II study of taxol in patients with non-small cell lung cancer (NSCLC) who have failed platinum containing chemotherapy. Proc Am Soc Clin Oncol 13: 363, 1994.
27. Alberola V, Cortesi E and Juan O: Weekly paclitaxel in the treatment of metastatic and/or recurrent non-small cell lung cancer. Crit Rev Oncol Hematol 44: S31-S41, 2002.
28. Socinski M et al: Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV non-small cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel. Cancer 95(6): 1265-1273, 2002.
29. Koumakis G et al: Is weekly paclitaxel superior to paclitaxel given every 3 weeks? Results of a phase II trial. Lung Cancer 35(3): 315-317, 2002.